Holen Sie sich die Stockscreener-App
51.24
1.24%
0.63
Handel nachbörslich:
51.00
-0.24
-0.47%
Schlusskurs vom Vortag:
$50.61
Offen:
$50.32
24-Stunden-Volumen:
2.34M
Relative Volume:
0.89
Marktkapitalisierung:
$12.70B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$833.42M
KGV:
16.98
EPS:
3.0172
Netto-Cashflow:
$917.69M
1W Leistung:
-5.23%
1M Leistung:
-8.12%
6M Leistung:
+16.67%
1J Leistung:
+33.19%
1-Tages-Spanne:
$50.02
$51.29
1-Wochen-Bereich:
$49.97
$54.02
52-Wochen-Spanne:
$33.76
$57.57
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
51.24 | 12.48B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law - The AI Journal
EXEL|Exelixis Inc|Price:50.990| - TradingKey
Farallon Capital (EXEL) discloses 13.99M-share Exelixis stake at $308M cost - Stock Titan
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL) - GlobeNewswire
Exelixis Inc (EXEL) Director Mary Beckerle Sells 9,812 Shares - GuruFocus
Annex Advisory Services LLC Makes New Investment in Exelixis, Inc. $EXEL - marketbeat.com
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada
Exelixis director Mary Beckerle sells $526k in shares - Investing.com
Exelixis director Mary Beckerle sells $526k in shares By Investing.com - Investing.com South Africa
Insider Selling: Exelixis (NASDAQ:EXEL) Director Sells $526,511.92 in Stock - marketbeat.com
Exelixis (EXEL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Exelixis (EXEL) director Beckerle sells 9,812 shares via Rule 10b5-1 plan - Stock Titan
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL) - Business Wire
AQR Capital discloses 11.0M-share Exelixis (EXEL) position at 4.39% ownership - Stock Titan
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis - PR Newswire
Exelixis (EXEL) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL) - PR Newswire
EXELIXIS, INC. SEC Filing (Aug 10, 2026) - stocktitan.net
Exelixis, Inc. (EXEL) Stock Analysis: Exploring Growth Potential in Oncology with a Strong ROE - DirectorsTalk Interviews
Bank of America Corp DE Sells 578,181 Shares of Exelixis, Inc. $EXEL - marketbeat.com
Exelixis, Inc. $EXEL Shares Acquired by Assenagon Asset Management S.A. - marketbeat.com
Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EXELIXIS INCDRN (E2XE34.SA) Q1 FY2026 earnings call transcript - Yahoo Finance
Amundi Sells 121,348 Shares of Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Exelixis Inc (EXEL) Stock News Today - TradingKey
Quantinno Capital Management LP Boosts Holdings in Exelixis, Inc. $EXEL - marketbeat.com
Exelixis (EXEL) Stock Drops As Guidance Cut Clouds Profit Strength - Sahm
EXELIXIS INC EXELIXIS ORD SHS (0IJO.L) Q4 FY2025 earnings call transcript - Yahoo Finance
Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot - Yahoo Finance
Exelixis, Inc. Stock 12‑Month Price Target Raised to $52.62, Implies 7% Downside - TradingView
EXELIXIS INC : LEERINK PARTNERS CUTS TO MARKET PERFORM FROM OUTPERFORM - Bitget
Exelixis (NASDAQ:EXEL) Rating Lowered to "Market Perform" at Leerink Partners - MarketBeat
EXEL Maintained by Truist Securities -- Price Target Lowered to $52.00 - GuruFocus
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View - Yahoo Finance
Stifel Nicolaus Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price - marketbeat.com
Exelixis, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:EXEL) 2026-08-06 - Seeking Alpha
Zacks Research Predicts Exelixis' Q3 Earnings (NASDAQ:EXEL) - marketbeat.com
Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong C - GuruFocus
EXELIXIS INC : STIFEL RAISES TARGET PRICE TO $51 FROM $47 - Bitget
Exelixis Q2 Earnings Call Highlights - MarketBeat
Exelixis (NASDAQ:EXEL) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Exelixis Inc (EXEL) Beats EPS Estimate with $0.82 and Reports Re - GuruFocus
Transcript : Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Earnings call transcript: Exelixis tops q2 2026 EPS view, shares fall after hours - Investing.com
Exelixis (EXEL) Tops Q2 Earnings Estimates - Yahoo Finance
Exelixis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
EXELIXIS INC EXELIXIS ORD SHS (0IJO.L) Q2 FY2026 earnings call transcript - finance.yahoo.com
(EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B - marketscreener.com
Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M - marketscreener.com
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):